Category: CBDiary

$407 for lab testing an LB?

California’s Medical Cannabis Regulation and Safety Act has been passed by the legislature, signed by the governor, and the Administrative State needs until January 1, 2018 to implement it. Dale Gieringer of California NORML reports: “Regulatory costs due to MCRSA are estimated to run between $225 and $873 per pound, according to an economic analysis by the University of California Agricultural Issues Center.  “Over half of the costs are accounted for by testing requirements. This analysis doesn’t include taxes.  The Prop 64 cultivation tax comes to $148/pound —less than the estimated cost of testing.  The analysis also estimates that adult-use production will be...

Read More

MJ vs ETOH —Take 2

“I don’t think I ever had a single shift where at least one of the patients I was taking care of was in that hospital bed at least partially due to their use of alcohol.” —Lanny Swerdlow, RN. Lanny Swerdlow asked in an email  if  “Dr. Mikuriya tried to get the study (Cannabis as a Substitute for Alcohol, which had run in O’Shaughnessy’s) published in a peer-reviewed journal and got turned down?”  Our off-the-top response is hereby corrected and expanded. Thanks to Jerry Mandel, Ethan Russo, MD, and Shobhit Arora, MD, for their input.   Tod had written a case report,...

Read More

‘Treatment’ Providers Ponder MJ Legalization

Kevin Hill’s paper in JAMA March 14, “Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders,” caught the attention of Diane Dickinson, MD. Hill is an addiction specialist at McLean Hospital, an affiliate of Harvard Medical School. He begins with an expression of concern:  “Health care professionals often are concerned about whether cannabis use will lead to psychiatric illnesses such as substance use disorders, anxiety disorders, or mood disorders among their patients. Many stakeholders are concerned that an association between cannabis use and psychiatric illnesses will lead to a steady increase in these illnesses as more states...

Read More

Dr. Scott Gottleib to head FDA

GW Pharmaceuticals, Insys, and other companies seeking FDA approval for cannabinoid drugs must have breathed a sigh of relief when Trump chose Scott Gottleib, MD, to head the agency, instead of Jim O’Neill, a libertarian who was in the running. O’Neill may have ditched the agency’s proof-of-efficacy requirement. (It has only been since 1962, BTW,  that the FDA has required drug companies to submit data proving the effectiveness of a new drug. Till then approval was based on evidence of safety.) O’Neill reportedly praised the idea of “letting the market decide” whether new drugs actually work. About Scott Gottleib, Wikipedia tells us: Prior to attending medical...

Read More

Listening to Tylenol

 At the March 12 meeting of the Society of Cannabis Clinicians, Bonni Goldstein, MD —in the course of an extremely informative talk on cannabis in the treatment of autism and epilepsy— remarked that she was “mortified” that she had prescribed so much Tylenol in her years as a pediatrician. For those who have not yet heard the news…  The active ingredient in Tylenol, acetaminophen, is the most widely used drug in the US —and it has the narrowest therapeutic ratio of any drug sold over the counter. The “therapeutic ratio” of a drug compares the amount required to produce harmful effects...

Read More